Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
A forum for researchers, students and applicants in the field of cyclodextrin technology
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to
— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care
Since the COVID-19 pandemic began, Gilead has worked diligently to ramp up production and rapidly expand the supply of our
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With
Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. The multiyear agreement will support efforts to
The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to